Trial Profile
A Phase I, Open-Label Study to Assess the Pharmacokinetics and Relative Bioavailability of AZD4635 in Non-Smoking Healthy Male Subjects, With the Option to Assess Food Effect, pH Effect and Absolute Bioavailability
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Apr 2023
Price :
$35
*
At a glance
- Drugs Imaradenant (Primary) ; Imaradenant (Primary) ; Lansoprazole
- Indications Cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Pharmacokinetics
- Acronyms Rel Bio
- Sponsors AstraZeneca
- 13 Apr 2023 Results reporting PK and safety from two phase 1 clinical studies (D8730C00007 and D8730C00002) published in the British Journal of Clinical Pharmacology
- 24 Jun 2020 Results, pooled analysis of data form two phase I studies (Phase 1 Study in healthy volunteers (N=20) and another study in Cancer patients (N=121)), assessing pharmacokinetics results to provide dosing and formulation recommendation, presented at the 111th Annual Meeting of the American Association for Cancer Research - II
- 10 Apr 2019 Status changed from active, no longer recruiting to completed.